Hong, J., Kwon, G. Y., Kang, M., Seo, S. I., & Park, S. H. (2024). Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society.
Παραπομπή σε μορφή Chicago (17η εκδ.)Hong, Joohyun, Ghee Young Kwon, Minyong Kang, Seong Il Seo, και Se Hoon Park. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society, 2024.
Παραπομπή σε μορφή MLA (9th εκδ.)Hong, Joohyun, et al. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society, 2024.